Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Carryn M Anderson"'
Autor:
Caiden Atienza, Andrew Shepard, Uwajachukwumma Uzomah, Shri Kiriti Rajan, Carryn M. Anderson, Joel Katzer, Samuel Rusu, Joel St-Aubin, Blake Smith, Daniel Hyer
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
This retrospective study evaluates the dosimetric benefits of adaptive radiotherapy for head and neck cancer patients. Five patients with node-positive oropharyngeal squamous cell carcinoma were treated with MR-guided radiotherapy using the Elekta Un
Externí odkaz:
https://doaj.org/article/33d82d7fe2104cf1b072bbd0432de689
Autor:
Kranti A. Mapuskar, Casey F. Pulliam, Ann Tomanek-Chalkley, Prerna Rastogi, Hsiang Wen, Sanjana Dayal, Benjamin R. Griffin, Diana Zepeda-Orozco, Amy L. Sindler, Carryn M. Anderson, Robert Beardsley, Eugene P. Kennedy, Douglas R. Spitz, Bryan G. Allen
Publikováno v:
Redox Biology, Vol 70, Iss , Pp 103022- (2024)
Purpose: Cisplatin contributes to acute kidney injury (AKI) and chronic kidney disease (CKD) that occurs with greater frequency and severity in older patients. Age-associated cisplatin sensitivity in human fibroblasts involves increased mitochondrial
Externí odkaz:
https://doaj.org/article/700536df35bc4b5690c5fab7c5eab07c
Autor:
Muhammad Furqan, Travis P. Snyders, Mohammed U. Saqlain, Sarah L. Mott, Douglas Laux, Anthony Snow, Carryn M. Anderson, John M. Watkins, Gerald H. Clamon
Publikováno v:
Cancer Medicine, Vol 8, Iss 6, Pp 2730-2739 (2019)
Abstract Background High‐dose cisplatin (Cis) is a preferred systemic agent for concurrent chemoradiation (CRT) in locally advanced head and neck squamous cell cancer (LAHNSCC) patients. As some patients are unable to tolerate Cis, this study compa
Externí odkaz:
https://doaj.org/article/25a0e21ebfab4140b5bcf8f1597d60a9
Autor:
Carryn M. Anderson, Christopher M. Lee, Deborah Saunders, Amarinthia E. Curtis, Neal E. Dunlap, Chaitali Nangia, Arielle S. Lee, Philip Kovoor, Voichita Bar-Ad, Abhinand V. Pedadda, Jon Holmlund, Matt Downs, Stephen T. Sonis
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:416-421
Avasopasem manganese (GC4419), an investigational selective dismutase mimetic radioprotector, reduced duration, incidence, and severity of severe oral mucositis (World Health Organization grade 3-4) in a phase 2b, randomized, double-blind trial of pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76e227ae3ab0d86631fdc455fb24daab
https://doi.org/10.1016/j.ijrobp.2022.06.063
https://doi.org/10.1016/j.ijrobp.2022.06.063
Autor:
Kranti A. Mapuskar, Emily J. Steinbach, Amira Zaher, Dennis P. Riley, Robert A. Beardsley, Jeffery L. Keene, Jon T. Holmlund, Carryn M. Anderson, Diana Zepeda-Orozco, John M. Buatti, Douglas R. Spitz, Bryan G. Allen
Publikováno v:
Antioxidants, Vol 10, Iss 9, p 1329 (2021)
Cisplatin is a chemotherapy agent commonly used to treat a wide variety of cancers. Despite the potential for both severe acute and chronic side effects, it remains a preferred therapeutic option for many malignancies due to its potent anti-tumor act
Externí odkaz:
https://doaj.org/article/0021957feb484ccdac2aff962e27ea4a
Autor:
Bryan G. Allen, Sudershan K. Bhatia, Carryn M. Anderson, Julie M. Eichenberger-Gilmore, Zita A. Sibenaller, Kranti A. Mapuskar, Joshua D. Schoenfeld, John M. Buatti, Douglas R. Spitz, Melissa A. Fath
Publikováno v:
Redox Biology, Vol 2, Iss C, Pp 963-970 (2014)
Cancer cells, relative to normal cells, demonstrate significant alterations in metabolism that are proposed to result in increased steady-state levels of mitochondrial-derived reactive oxygen species (ROS) such as O2•−and H2O2. It has also been p
Externí odkaz:
https://doaj.org/article/b33c13805b3e4342821a2e82435b3589
Autor:
Aaron T Seaman, Christopher Blake Sullivan, Nitin A. Pagedar, Carryn M. Anderson, Zaid Al-Qurayshi
Publikováno v:
Laryngoscope
OBJECTIVE To analyze the clinicodemographic characteristics and treatment outcomes of patients receiving postoperative radiation therapy (PORT) at a different treatment facility rather than the initial surgical facility for head and neck cancer. STUD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af3b9bce6fc63362ab5109b2d199250
https://doi.org/10.1002/lary.29033
https://doi.org/10.1002/lary.29033
Autor:
Randall J. Kimple, Danielle N. Margalit, Carryn M. Anderson, Daniel J. Ma, Sana D. Karam, Melvin L.K. Chua
Publikováno v:
Advances in Radiation Oncology
The SARS-CoV-2 pandemic has significantly impacted healthcare delivery around the world. Elective procedures and routine follow-ups have been cancelled and/or converted to tele-health visits by many systems. In this article, we focus on recommendatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abe61e1165ba1a0145f37d3da6823988
https://doi.org/10.1016/j.adro.2020.04.031
https://doi.org/10.1016/j.adro.2020.04.031
Impact of Treatment Time on Outcome for Resected Head and Neck Squamous Cell Carcinoma by HPV Status
Autor:
John M. Watkins, Anthony N. Snow, Carryn M. Anderson, John M. Buatti, Nicholas S. Andresen, Nitin A. Pagedar, Rodrigo Bayon, Sarah L. Mott
Publikováno v:
Clinical Oncology and Research. :1-7
Background and Purpose: Prior investigations have demonstrated an inverse correlation between the interval from resection of head and neck squamous cell carcinoma (HNSCC) to radiotherapy (RT) completion (overall treatment time; OTT) and disease contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4e36ab8058638e956792f18ac19c32d
https://doi.org/10.31487/j.cor.2020.02.09
https://doi.org/10.31487/j.cor.2020.02.09
Autor:
Howard P Safran, Kathryn Winter, David H Ilson, Dennis Wigle, Thomas DiPetrillo, Michael G Haddock, Theodore S Hong, Lawrence P Leichman, Lakshmi Rajdev, Murray Resnick, Lisa A Kachnic, Samantha Seaward, Harvey Mamon, Dayssy Alexandra Diaz Pardo, Carryn M Anderson, Xinglei Shen, Anand K Sharma, Alan W Katz, Jonathan Salo, Kara L Leonard, Jennifer Moughan, Christopher H Crane
Publikováno v:
The Lancet. Oncology. 23(2)
Trastuzumab is a monoclonal antibody against HER2 (also known as ERBB2). The primary objective of the NRG Oncology/RTOG-1010 trial was to establish whether trastuzumab improves disease-free survival when combined with trimodality treatment (paclitaxe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a941128886a87cf6b1452d19a978e0b8
https://pubmed.ncbi.nlm.nih.gov/35038428
https://pubmed.ncbi.nlm.nih.gov/35038428